TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01677871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2HRZE/4HR
Description: Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2HRLE/4HR
Description: Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 9HLE
Description: Isoniazid+ Levofloxacin+ Ethambutol for 9 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9RLE
Description: Rifampicin + Levofloxacin+ Ethambutol for 9 months
Study: NCT02778984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuadraLite masks
Description: The intervention is identical in the two group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard mask
Study: NCT01052883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
Description: DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment C\], then after 7 days off treatment start DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment D\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
Description: DRV 800 mg new formulation tablet/rtv 100mg tablet in the morning of Day 3 after food+ rtv 100 mg 1/day on Day 1-5 \[Treatment B\], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment A\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
Description: DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment D\], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment C\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
Description: DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment A\], then after 7 days off treatment start DRV 800 mg new formulation tablet in the morning of Day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment B\]
Study: NCT00004227

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study: NCT04068948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Description: This intervention assesses a child's behavioral outcome for dental procedural sedation in combination with midazolam and hydroxyzine. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Description: This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyzine
Description: This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
Study: NCT03359369

Intervention type: DIAGNOSTIC_TEST
Intervention: level of serum cholesterol and triglyceride
Description: other

Intervention type: DIAGNOSTIC_TEST
Intervention: level of serum cholesterol and triglyceride
Description: other
Study: NCT04570618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unblinded AlgoDx Sepsis Prediction Algorithm
Description: When applicable, a sepsis prediction alert is displayed in the AlgoDx Medical Device Software.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Blinded AlgoDx Sepsis Prediction Algorithm
Description: Standard of Care, i.e. no sepsis prediction alert.
Study: NCT02459561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoBarrier TM Gastrointestinal Liner
Description: If subjects are randomised into the EndoBarrier Group of the trial they will receive the device for 12 months followed a 12 months follow-up period.

Intervention type: OTHER
Group type: OTHER
Intervention: Best Medical Care
Description: If subjects are randomised into the Control Group of the trial they will receive best medical care and dietitian advice for 12 months followed a 12 months follow-up period.
Study: NCT03063606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Description: CBT specialist treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB Medication (on-going from acute treatment)
Description: Naltrexone/bupropion combination (on-going blinded pharmacotherapy from acute treatment consisting of either naltrexone/bupropion or placebo)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NB Medication (on-going from acute treatment)
Description: Naltrexone/bupropion combination (on-going blinded pharmacotherapy from acute treatment consisting of either naltrexone/bupropion or placebo)
Study: NCT02664519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forearm exercise training
Description: Subjects will be asked to squeeze a tennis ball repeatedly for at least 30 min/day for 28 days at an approximate rate of 20 squeezes/min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forearm exercise training
Description: Subjects will be asked to squeeze a tennis ball repeatedly for at least 30 min/day for 28 days at an approximate rate of 20 squeezes/min.
Study: NCT00712478

Intervention type: DRUG
Intervention: insulin
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT03877003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs
Description: Eggs: Consume 3 eggs per day for 4 weeks Choline supplement: Consume 1.5 pills per day for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs
Description: Eggs: Consume 3 eggs per day for 4 weeks Choline supplement: Consume 1.5 pills per day for 4 weeks
Study: NCT02461199

Intervention type: BIOLOGICAL
Intervention: Fecal microbiota transplantation
Description: Transplantation of 100 ml of fecal microbiota suspension obtained from healthy unrelated donor in two consecutive days via the nasoduodenal tube
Study: NCT03938831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: dexmedetomidine 0.5 micg/kg/hr infusion during operation and followed by 0.2 mic/kg/hr with fentanyl-based PCA mixture for 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl-based PCA infusion
Description: Fentanyl-based PCA infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl-based PCA infusion
Description: Fentanyl-based PCA infusion
Study: NCT00965289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab infusion on day 1 dose: 375mg/m²
Study: NCT01892371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Given PO
Study: NCT02294617

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotrol Inhaler
Description: Subjects will use the Nicotrol Inhaler for 3 days.
Study: NCT01598870

Intervention type: OTHER
Intervention: Diagnostic tests
Description: Leukocyte count by automated counters; reagent strips for leukocyte esterase and for lactoferrin; ascitic fluid pH; leukocyte cytometry; bacterial DNA detection and quantification.
Study: NCT03675256

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immediate Gardasil 9, delayed MenVeo vaccine
Description: Intervention is immediate administration of 9-valent HPV vaccine and delayed MenVeo vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: immediate MenVeo vaccine, delayed Gardasil 9
Description: Intervention is immediate administration of MenVeo vaccine and delayed administration of Gardasil 9

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immediate Cervarix, delayed MenVeo vaccine
Description: Intervention is immediate administration of bivalent HPV vaccine and delayed MenVeo vaccine
Study: NCT03399604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIQ861 Inhaled Treprostinil
Description: LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
Study: NCT00921050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levothyroxine sodium
Description: Daily intake (fasting) levothyroxine bimonthly adjusted; to keep TSH between 0.5 to 2.5 mUI/L range. Start with 12.5mcg an investigator other than the caregiver will review the TSH measurements to adjust levothyroxine dose that will contain the coded bottle with the pils given to patient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: excipient without levothyroxine (placebo)
Description: Daily intake (fasting) a pill. bimonthly adjusted; an investigator other than the caregiver will review the TSH measurements and pretend to adjust dose contained in the coded bottle with the pills given to patient.
Study: NCT03606291

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: isotoxic hypofractionation
Description: the normal tissue limits are uniform, such as: V20% ≤ 30%, spinal cord 0\> 45Gy, etc., and used hypofractionated radiotherapy technology so that each patient received the maximum individualized radiation dose as possible
Study: NCT02835144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TIQAAM_therapy
Description: The treatment program consists of TIQAAM therapy blocks to three priority areas: promoting change and motivation, relapse prevention and relapse management, and promote resource and euthymic activities to increase the abstinence motivation. The TIQAAM is based on behavioral approaches as well as motivational interviewing of Miller and Rollnick.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: This intervention is a psychoeducation module pertaining to substance use disorders.
Study: NCT04283188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavioral therapy
Description: Participants will be provided with the option to continue treatment with their study therapist. For those who elect to continue with DBT sessions, they will discuss frequency of sessions with their therapist, in addition to selecting type of sessions (individual and/or family skills). Participants who elect not to continue with DBT sessions at the time of enrollment will retain the option of being able to request additional sessions at any point during the 12-month study. Irrespective of participation in additional DBT sessions, all participants will be asked to complete follow-up interviews and questionnaires.
Study: NCT00192543

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet of fish and fruit
Description: fish and fruit in specified quantities

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: fruit and fish
Description: no drugs

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet only
Description: Fish and fruit

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: regular diet
Description: no change in regular diet
Study: NCT00537537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telbivudine
Study: NCT00077493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BL22 immunotoxin
Description: BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 OR on days 1, 3, 5, 7, 9, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) or unconfirmed CR (CRu) receive 2 additional courses beyond CR or CRu for a maximum of 6 courses.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: antibody-drug conjugate therapy
Description: CD22 antibody, RFB4 on day 7
Study: NCT00537537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telbivudine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telbivudine
Study: NCT03464526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orvepitant
Description: Tablet, once daily, oral
Study: NCT03590704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitaltape® bandage
Description: The neuromuscular bandage will be applied after skin antisepsis with 70% alcohol. A 5 cm width Vitaltape® neuromuscular bandage will be used. For the bandage application, a distal base (anchor) with two centimeters of diameter will be maintained with maximum stretching on the seroma and finalized with another base no stretching, of 2 cm, in the proximal region. How many bundles of bandages are required according to the patient's body characteristics and aspect of the flotation region.
Study: NCT03384225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Study: NCT03464526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orvepitant
Description: Tablet, once daily, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orvepitant
Description: Tablet, once daily, oral
Study: NCT03384225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study: NCT03464526

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, once daily, oral
Study: NCT03154476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil will be initiated at 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week and 20 mg 3 times per day from the third week to the end of the study period, 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching study drug
Study: NCT03384225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Study: NCT00125372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib (Tarceva) and bexarotene (Targretin)
Description: Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy
Study: NCT02656901

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: auto total endovenous anesthesia
Description: a closed-loop controller guided by the BIS steering the infusion pumps (Alaris Medical UK Ldt, Hants, Uk) as already approved by ClinicalTrials.gov Identifier: NCT00392158

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Manual Desflurane anesthesia
Description: General anesthesia will be maintained with desflurane (Baxter D-Vapor Desflurane Vaporiser) to obtain a BIS value as close as possible to 50 and between 40

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Manual Sevoflurane anesthesia
Description: General anesthesia will be maintained with sevoflurane ( Baxter Vapour 2000 Sevoflurane Vapouriser) to obtain a BIS value as close as possible to 50 and between 40 and 60.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Manual total endovenous anesthesia
Description: In ManualTIVA group, the anesthesia will be maintained with propofol (Injectomat TIVA Agilia, Fresenius Kabi, Bad Hamburg, Germany) to obtain a BIS value as close as possible to 50 and between 40 and 60.
Study: NCT03610906

Intervention type: PROCEDURE
Intervention: Tumor and Blood Specimens
Description: If available, specimen will be sampled from within the tumor, and not include portions of the tumor capsule. If the tumor includes a cyst, fluid from the cyst will be sampled if available. For each tumor specimen, a companion sample of blood that would otherwise be disposed of through usual clinical practice in the operating room will also be collected.
Study: NCT01769703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran 110/150 mg BID
Description: Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.
Study: NCT02020460

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subdural trial lead

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural trial lead
Study: NCT03604068

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RecoveryRx
Description: A pulsed shortwave therapy medical device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham RecoveryRx
Description: A sham pulsed shortwave therapy medical device
Study: NCT01796262

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: docosahexaenoic acid
Description: Supplementation with DHA Richoil 250mg pearl b.i.d. for six months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat germ oil
Description: Wheat germ oil 250 mg pearl b.i.d. for six months
Study: NCT00917085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin-to-Skin contact
Description: Infants in the Skin-to-Skin group also had standard care provided by hospital staff. In addition, the researchers facilitated skin-to-skin contact by placing diaper-clad infants prone between their mothers' breasts as soon as possible after birth. Thereafter the infants and their mothers experienced skin-to-skin contact as often as possible and for as long as possible each time throughout the protocol.
Study: NCT01602549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 (25 mg tablet)
Description: 25 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablet
Study: NCT04470128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage I: HSK21542 0.5 μg/kg
Description: intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage I: HSK21542 1 μg/kg
Description: intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542 0.5 μg/kg
Description: intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542 1 μg/kg
Description: intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542 2 μg/kg
Description: intravenous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous injection
Study: NCT00851253

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Given in 2 fractionated doses or 5 fractionated doses

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Given in 2 fractionated doses or 5 fractionated doses
Study: NCT02884830

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure
Description: positive airway pressure given by a medical device through a nasal mask

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: continuous positive airway pressure
Description: positive airway pressure given by a medical device through a nasal mask
Study: NCT00960713

Intervention type: DRUG
Intervention: Rituximab (MABTHERA® or RITUXAN®).
Description: patients can be included in the study whatever the dosage used. Most patients will receive a classical 375 mg/m2 dose every week during four times (J0-J7-J14-J21).
Study: NCT05066035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: The study investigators administer neostigmine at the end of operation to reverse neuromuscular blockade, and the routine dose of the intravenous neostigmine is 0.05 mg/kg and atropine 0.02 mg/kg. The dose is given in a single syringe, and later they administer this reversal medication before extubation.~In the case of a residual block, the neostigmine group of patients receives a rescue dose of neostigmine at a dose of 0.03 mg/kg in the operating room fifteen minutes before discharge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: The study investigators administer the routine full-dose neostigmine reversal medication and three minutes later, they administer an intravenous bolus dose of 1 mg/kg sugammadex in a different syringe prepared earlier as a reversal agent. The anesthesia team considers using an intravenous rescue dose of 1 mg/kg sugammadex for this group of patients in the recovery room if patients do not show a complete recovery of TOF ratio equal to \>0.9 in the recovery room before discharge to the ward.
Study: NCT01788072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Oxytocin
Description: 24 IU taken twice daily (BID), in the morning and at noon/early afternoon

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 IU taken twice daily (BID), in the morning and at noon/early afternoon